Emerging Therapies Using Senolytic Combinations to Extend Functional Healthspan

Abstract

Cellular senescence is an established hallmark of aging, contributing to the decline in tissue function and onset of various age-related diseases. Recent advances in the field of geroscience have highlighted senolytic agents drugs that selectively clear senescent cells as a promising therapeutic approach to extend functional healthspan. This review synthesizes the latest evidence on senolytic combinations, exploring their mechanistic basis, clinical impact, and implications for the management of age-associated conditions. Emphasis is placed on research findings from preclinical studies and emerging clinical trials, their translational relevance, and practical considerations for integrating senolytic therapy into future medical practice.

Introduction

The global population is aging at an unprecedented rate, with a commensurate rise in chronic diseases and functional decline. Traditional strategies have focused on disease-specific management, but geroscience now seeks to target fundamental mechanisms of aging, such as cellular senescence, to delay or prevent multiple age-related pathologies simultaneously. Senolytic therapies, particularly those utilizing drug combinations to potentiate efficacy and minimize toxicity, are garnering significant attention as a means to extend the healthspan the period of life spent in good health rather than merely prolonging lifespan. This article provides an in-depth examination of the scientific rationale, recent research, and clinical implications of senolytic combination therapies in the context of healthy aging.

Epidemiology / Disease Burden

Aging is the strongest risk factor for a myriad of chronic diseases, including cardiovascular disease, diabetes, neurodegenerative disorders, osteoarthritis, and cancer. According to the World Health Organization, by 2050, the population over age 60 is projected to double, reaching 2.1 billion globally. This demographic shift poses significant challenges, with functional decline, frailty, and multimorbidity leading to increased healthcare utilization and diminished quality of life. The accumulation of senescent cells is now recognized as a key contributor to this burden, driving systemic inflammation, tissue dysfunction, and impaired regeneration. Thus, interventions that target senescent cells have the potential to mitigate the escalating burden of age-related morbidity.

Pathophysiology

Cellular senescence is a state of stable cell cycle arrest triggered by various stressors, including telomere attrition, DNA damage, oncogene activation, and mitochondrial dysfunction. Senescent cells secrete a pro-inflammatory and tissue-remodeling milieu known as the senescence-associated secretory phenotype (SASP). While transient senescence serves beneficial roles in wound healing and tumor suppression, persistent accumulation of senescent cells disrupts tissue homeostasis, propagates chronic inflammation ("inflammaging"), and impairs organ function. These pathophysiological mechanisms are implicated in the progression of multiple age-related diseases, highlighting the rationale for therapeutic senolysis.

Risk Factors

Key risk factors for excessive cellular senescence include chronological aging, exposure to chemotherapeutic agents and radiation, metabolic syndrome, chronic infections, obesity, and genetic predispositions affecting DNA repair and mitochondrial function. Lifestyle factors such as poor diet, physical inactivity, and smoking further contribute to the senescence burden. Understanding these risk factors is crucial for identifying patient populations that may benefit most from senolytic interventions.

Clinical Features

Senescence-driven dysfunction manifests clinically as frailty, sarcopenia, osteoarthritis, cognitive impairment, and delayed wound healing. Patients often present with non-specific symptoms such as fatigue, reduced exercise tolerance, and increased susceptibility to infections. In diseases such as idiopathic pulmonary fibrosis, diabetic nephropathy, and atherosclerosis, senescent cell accumulation has been directly linked to disease pathogenesis, severity, and progression.

Diagnosis

Currently, the diagnosis of cellular senescence in clinical practice is limited by the lack of specific, non-invasive biomarkers. Laboratory methods such as senescence-associated β-galactosidase staining, p16INK4a and p21 expression, and SASP profiling are primarily research tools. Ongoing efforts are directed at developing circulating biomarkers, imaging modalities, and molecular assays to enable patient stratification and monitoring of senolytic therapy responses in clinical settings.

Treatment & Management

Traditional management of age-related diseases has focused on symptomatic relief and disease-specific pharmacotherapies. However, these approaches do not address the underlying drivers of aging. Senolytic therapies represent a paradigm shift, aiming to selectively eliminate senescent cells and thereby restore tissue function and resilience. Early-generation senolytics, such as dasatinib (a tyrosine kinase inhibitor) and quercetin (a flavonoid), have demonstrated efficacy in preclinical models, but single-agent approaches are limited by incomplete clearance and potential toxicity. Combination regimens are now being investigated to enhance senolytic potency, widen the therapeutic window, and reduce adverse effects.

Recent Advances / Emerging Therapies

Recent research has focused on optimizing senolytic combinations to maximize clinical benefit. Notably, the dasatinib and quercetin (D+Q) combination has shown synergistic effects in models of idiopathic pulmonary fibrosis, diabetic nephropathy, and osteoarthritis, leading to reduced senescent cell burden and improved functional outcomes. Novel combinations, such as navitoclax (a Bcl-2 family inhibitor) with other small molecules, are under investigation for their enhanced ability to induce apoptosis in diverse senescent cell populations. Other promising agents include fisetin, piperlongumine, and HSP90 inhibitors, often used in rational combinations based on complementary mechanisms of action. Early-phase clinical trials have demonstrated safety and preliminary efficacy in improving physical function and biomarkers of aging in elderly and high-risk patient cohorts. Importantly, these therapies are being tested in intermittent dosing schedules to minimize off-target effects and preserve tissue homeostasis. Recent guidelines and consensus statements emphasize the need for rigorous clinical evaluation, long-term safety monitoring, and biomarker development to guide therapy.

Guideline Recommendations

While senolytic therapies remain investigational, geriatric and geroscience societies recommend that clinicians stay informed about ongoing trials, emerging safety data, and evolving patient selection criteria. Current recommendations encourage the enrollment of eligible patients in clinical trials and the integration of senescence biology concepts into the broader context of chronic disease management. Guideline panels highlight the importance of multidisciplinary collaboration among geriatricians, internists, and researchers to develop standardized protocols for future senolytic interventions.

Conclusion

Senolytic combination therapies represent a transformative approach to extending functional healthspan by targeting fundamental aging mechanisms. As evidence accumulates from preclinical and early clinical studies, these interventions hold promise for reducing the burden of age-related diseases and improving quality of life in an aging population. Continued research, robust clinical trials, and the development of reliable biomarkers are essential to translating senolytic strategies into routine clinical practice. Healthcare professionals should remain engaged with this rapidly evolving field to optimize patient outcomes and contribute to the future of healthy aging.